LungFamily PracticeNursingHematology & OncologyPulmonologyInternal MedicinePathologyRadiologyGeriatricsLung CancerCancerRadiationGeneral HealthSurgery
HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
FRIDAY, Oct. 27, 2017 (HealthDay News) -- For patients with stage I non-small-cell lung cancer (NSCLC), the odds of receiving radiation therapy (RT) or surgery increased from 2000 to 2010, with improved survival during the same period, according to a study published online Oct. 26 in the Annals of Thoracic Surgery.
Nirav S. Kapadia, M.D., from Dartmouth Hitchcock Medical Center in Lebanon, New Hampshire, and colleagues conducted a population-based comparative effectiveness study using Surveillance, Epidemiology, and End Results-18 data from 2000 to 2010 for stage I NSCLC patients. A total of 40,589 patients (62 percent) underwent surgery, 10,048 (15 percent) received RT, 2,130 (3 percent) received both surgery and RT, and 11,537 (18 percent) received neither surgery nor RT.
The researchers found that there was an increase annually in the odds of either receiving definitive RT or undergoing surgery relative to the odds of receiving no treatment (odds ratios, 1.04 and 1.05, for RT and surgery, respectively). The proportion of sublobar resections increased steadily among surgical patients, from 12.9 to 17.9 percent. Each year there was a 3.5 percent decrease in the two-year risk of death for all patients (hazard ratio, 0.965), driven mainly by improved survival for surgical and RT patients (annualized hazard ratios, 0.959 and 0.942, respectively).
"Between 2000 and 2010, stage I NSCLC patients were more likely to receive definitive treatment with either surgery or RT, leading to a decline in the number of untreated patients," the authors write.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at firstname.lastname@example.org with any questions.
Updated on May 29, 2022
Read this Next
Other Trending Articles